3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
19
Carcinoma, Hepatocellular
18
Pancreatic Neoplasms
14
Colorectal Neoplasms
12
Esophageal Neoplasms
9
Neoplasm Metastasis
8
Esophageal Squamous Cell Carcinoma
7
Biliary Tract Neoplasms
7
Lung Neoplasms
6
Liver Neoplasms
6
Cholangiocarcinoma
6
Breast Neoplasms
6
Neoplasms
5
Colonic Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Melanoma
3
Sarcoma
2
Rectal Neoplasms
2
Advanced Pancreatic Cancer
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Resectable Esophageal Squamous Cell Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Cancer Metastatic
1
Ovarian Neoplasms
1
Oligometastatic Gastrointestinal Cancer
1
Interventions
Gemcitabine
3
folfirinox
2
Oxaliplatin
2
Irinotecan
2
toripalimab
1
surufatinib
1
sintilimab
1
devimistat
1
chloroquine diphosphate
1
balstilimab
1
Taxes
1
Paclitaxel
1
Leucovorin
1
Injections
1
Immune Checkpoint Inhibitors
1
Drug Therapy
1
Cisplatin
1
Chloroquine
1
Celecoxib
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Cancer Metastatic
×
Injections
×
Gastrointestinal
×
Clear all
NCT06752811
2026-02-10
pompom
Shanghai Yizhong Pharmaceutical Co., Ltd.
Phase 3
Recruiting
416 enrolled